newsfilter
← Latest News
GlobeNewswire·

Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

– Commercialization plans for lorundrostat are on track ahead of PDUFA target date of December 22, 2026 – – New analyses from the pivotal Launch-HTN trial showed 46% of participants with uncontrolled or resistant